Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Other Non-Current Assets for 3 consecutive years, with $28.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Non-Current Assets fell 11.84% year-over-year to $28.8 million; the TTM figure through Dec 2025 stood at $28.8 million (down 11.84% YoY), while the FY2025 annual figure was $28.8 million, up 91.0% from the prior year.
• Other Non-Current Assets eased to $28.8 million in Q4 2025 per TLX's latest filing, from $32.7 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $32.7 million in Q4 2024 and bottomed at $381480.4 in Q4 2023.
• Historically, Other Non-Current Assets has averaged $20.6 million across 3 years, with a median of $28.8 million in 2025.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 8471.3% — and 2025, when it slipped 11.84%.
• Telix Pharmaceuticals' Other Non-Current Assets stood at $381480.4 in 2023, then soared by 8471.3% to $32.7 million in 2024, then dropped by 11.84% to $28.8 million in 2025.
• Business Quant data shows TLX's Other Non-Current Assets at $28.8 million in Q4 2025, $32.7 million in Q4 2024, and $381480.4 in Q4 2023.